MA56507A - Nouveaux inhibiteurs d'egfr - Google Patents

Nouveaux inhibiteurs d'egfr

Info

Publication number
MA56507A
MA56507A MA056507A MA56507A MA56507A MA 56507 A MA56507 A MA 56507A MA 056507 A MA056507 A MA 056507A MA 56507 A MA56507 A MA 56507A MA 56507 A MA56507 A MA 56507A
Authority
MA
Morocco
Prior art keywords
egfr inhibitors
new egfr
new
inhibitors
egfr
Prior art date
Application number
MA056507A
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Stephen Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Roger David Norcross
Christa Ulrike Obst-Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA56507A publication Critical patent/MA56507A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
MA056507A 2019-06-21 2020-06-19 Nouveaux inhibiteurs d'egfr MA56507A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181772 2019-06-21

Publications (1)

Publication Number Publication Date
MA56507A true MA56507A (fr) 2022-04-27

Family

ID=67001684

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056507A MA56507A (fr) 2019-06-21 2020-06-19 Nouveaux inhibiteurs d'egfr

Country Status (20)

Country Link
US (2) US20220315591A1 (fr)
EP (2) EP3986567B1 (fr)
JP (2) JP7530390B2 (fr)
KR (1) KR20220024096A (fr)
CN (2) CN113993590B (fr)
AR (2) AR121167A1 (fr)
AU (1) AU2020296933A1 (fr)
BR (1) BR112021024810A2 (fr)
CA (1) CA3139171A1 (fr)
CL (1) CL2021003373A1 (fr)
CO (1) CO2021016967A2 (fr)
CR (1) CR20210614A (fr)
IL (1) IL287806A (fr)
MA (1) MA56507A (fr)
MX (1) MX2021015889A (fr)
PE (1) PE20220807A1 (fr)
PH (1) PH12021553018A1 (fr)
TW (2) TW202115073A (fr)
WO (2) WO2020254547A1 (fr)
ZA (1) ZA202108775B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254565A1 (fr) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Inhibiteurs d'egfr pour le traitement du cancer
AR121167A1 (es) * 2019-06-21 2022-04-27 Hoffmann La Roche DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
IL326872A (en) 2019-11-11 2026-04-01 Dana Farber Cancer Inst Inc EGFR allosteric inhibitors and methods of using them
US20240002390A1 (en) * 2020-12-01 2024-01-04 Hoffmann-La Roche Inc. New indazole acetylene derivatives
WO2022117475A1 (fr) 2020-12-01 2022-06-09 F. Hoffmann-La Roche Ag Nouveaux dérivés d'indazole
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
CN121712509A (zh) 2023-05-04 2026-03-20 锐新医药公司 用于ras相关疾病或病症的组合疗法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
IL327306A (en) 2023-10-12 2026-05-01 Revolution Medicines Inc Macrocyclic RAS inhibitors
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025255438A1 (fr) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Procédés de traitement d'une maladie ou d'un trouble lié à la protéine ras
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon
WO2026090116A2 (fr) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026090245A1 (fr) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Utilisation d'inhibiteurs ras pour traiter un cancer
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009158369A1 (fr) 2008-06-25 2009-12-30 Schering Corporation Synthèse et utilisation d’agents antibactériens hétérocycliques
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
EP3294705B1 (fr) 2015-05-14 2021-07-21 The Wistar Institute Of Anatomy And Biology Inhibiteurs d'ebna1 et méthodes les utilisant
CA2987914C (fr) 2015-06-30 2022-09-13 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'egfr et methodes d'utilisation de ceux-ci
AR113299A1 (es) * 2017-06-02 2020-04-08 Hoffmann La Roche Compuestos de isoindolina
CA3103166A1 (fr) 2018-06-29 2020-01-02 F. Hoffmann-La Roche Ag Composes
WO2020254565A1 (fr) 2019-06-21 2020-12-24 F. Hoffmann-La Roche Ag Inhibiteurs d'egfr pour le traitement du cancer
CN113993589A (zh) * 2019-06-21 2022-01-28 豪夫迈·罗氏有限公司 新egfr抑制剂
AR121167A1 (es) * 2019-06-21 2022-04-27 Hoffmann La Roche DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Also Published As

Publication number Publication date
EP3986567B1 (fr) 2023-08-30
CA3139171A1 (fr) 2020-12-24
AR119207A1 (es) 2021-12-01
AR121167A1 (es) 2022-04-27
IL287806A (en) 2022-01-01
CN113993590B (zh) 2024-08-23
CN113993591A (zh) 2022-01-28
KR20220024096A (ko) 2022-03-03
JP7530390B2 (ja) 2024-08-07
CR20210614A (es) 2022-02-11
US20220315591A1 (en) 2022-10-06
WO2020254547A1 (fr) 2020-12-24
US20220112199A1 (en) 2022-04-14
JP2022537772A (ja) 2022-08-29
TW202115073A (zh) 2021-04-16
ZA202108775B (en) 2022-09-28
JP2022537771A (ja) 2022-08-29
PE20220807A1 (es) 2022-05-20
PH12021553018A1 (en) 2023-08-23
EP3986567A1 (fr) 2022-04-27
BR112021024810A2 (pt) 2022-01-25
CN113993590A (zh) 2022-01-28
TW202115070A (zh) 2021-04-16
EP3986567C0 (fr) 2023-08-30
WO2020254546A1 (fr) 2020-12-24
AU2020296933A1 (en) 2021-12-02
EP3986566A1 (fr) 2022-04-27
EP3986566B1 (fr) 2023-08-30
MX2021015889A (es) 2022-02-03
CO2021016967A2 (es) 2022-01-17
CL2021003373A1 (es) 2022-10-07
EP3986566C0 (fr) 2023-08-30
JP7561779B2 (ja) 2024-10-04

Similar Documents

Publication Publication Date Title
EP4007752C0 (fr) Inhibiteurs de kif18a
EP4007756C0 (fr) Inhibiteurs de kif18a
EP3986566C0 (fr) Nouveaux inhibiteurs de l'egfr
EP4197538A4 (fr) Inhibiteur du récepteur du facteur de croissance épidermique
MA51616A (fr) Inhibiteurs d'adn-pk
EP4007753C0 (fr) Inhibiteurs de kif18a
EP4003212A4 (fr) Marqueur de repère
EP3906029A4 (fr) Inhibiteurs de l'interaction ménine-mll
EP3852762A4 (fr) Nouveaux inhibiteurs de l'egfr quinazoline
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
EP3980011A4 (fr) Inhibiteurs de sarm1
DK4051688T3 (da) Cd73-hæmmere
EP3828822C0 (fr) Génie civil
EP3919491A4 (fr) Inhibiteur d'akt
EP3938358A4 (fr) Inhibiteurs de rad51
MA49006A (fr) Inhibiteurs d'ip6k
MA53648A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase
EP4076664C0 (fr) Inhibiteurs d' egfr
EP4030778A4 (fr) Casque d'écoute
EP3814324A4 (fr) Inhibiteurs de la cathepsine c
EP3986565C0 (fr) Nouveaux inhibiteurs de l'egfr
EP4076665C0 (fr) Inhibiteurs d' egfr
IL292656B1 (en) Inhibitors of adrenoreceptor adrac2
EP3976797A4 (fr) Inhibiteurs anti-crispr
EP3975220A4 (fr) Panneau d'affichage